Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qelbree in adolescents with ADHD
NCT03247556Phase 3Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Nov 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of viloxazine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition at Week 7. Started Nov 2017; status: completed.
02
Drugs
viloxazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03247556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03247556.